← Back to Search

Procedure

Cardioversion Devices for Atrial Fibrillation

N/A
Waitlist Available
Led By Brett Atwater, MD
Research Sponsored by Inova Health Care Services
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years
In AF on presentation with plan for DCCV in either the Electrophysiology lab or DCCV procedure area
Must not have
Patients with arrhythmias other than AF
Patients with untreated hyperthyroidism
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 minute after shock delivered
Awards & highlights

Summary

This trial compares two shock treatments for cardiac defibrillation to see which is more effective and has fewer side effects. #MedicalResearch

Who is the study for?
This trial is for adults over 18 with Atrial Fibrillation (AF) who are stable and have a plan for electrical cardioversion. They must be properly anticoagulated or cleared of intracardiac thrombi by imaging. It's not for those on other trials, with unstable AF, other arrhythmias, untreated hyperthyroidism, pregnancy, or potential non-compliance.
What is being tested?
The study compares two defibrillators: Zoll using a single 200J RBW shock and Lifepak using a single 360J BTE shock in patients with AF. Participants will be randomly assigned to one of the devices to see which is more effective at restoring normal heart rhythm.
What are the potential side effects?
Possible side effects from the cardioversion may include skin irritation or burns where the defibrillator pads are placed, discomfort in the chest area due to shocks, short-term heart rhythm problems post-procedure, and very rarely more serious complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have atrial fibrillation and am scheduled for a cardioversion procedure.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a heart rhythm problem that is not atrial fibrillation.
Select...
I have an overactive thyroid that hasn't been treated.
Select...
My heart condition causes unstable blood pressure.
Select...
I either lack proper blood thinning treatment or have confirmed no blood clots in my heart via scan.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 minute after shock delivered
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 minute after shock delivered for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The number of participants in normal sinus rhythm (NSR) by ECG after the first DCCV shock

Trial Design

4Treatment groups
Active Control
Group I: Lifepak defibrillator waveform used after unsuccessful second full output shock.Active Control1 Intervention
Participants who received first shock via Lifepak that do not have success after a second full output shock will be crossed over to the Zoll defibrillator waveform and receive up to 2 full output shocks with a minimum of 1 minute between each shock to ascertain the outcome of the immediately prior shock.
Group II: Output synchronized to 200J using Zoll Rectilinear Biphasic Waveform (RBW) defibrillatorActive Control1 Intervention
Participants receiving Direct Current Cardioversion (DCCV) using full output Rectilinear Biphasic Waveform (RBW) shocks from a Zoll defibrillator (200 Joules) up to 2 shocks.
Group III: Output synchronized to 360J Lifepak Biphasic Truncated Exponential Waveform (BTE) defibrillatorActive Control1 Intervention
Participants receiving Direct Current Cardioversion (DCCV) using full output Biphasic Truncated Exponential Waveform (BTE) shocks from a Physiocontrol/Medtronic Lifepak defibrillator (360 Joules) up to 2 shocks.
Group IV: Zoll defibrillator waveform used after unsuccessful second full output shock.Active Control1 Intervention
Participants who received first shock via Zoll that do not have success after a second full output shock will be crossed over to the Lifepak defibrillator waveform and receive up to 2 full output shocks with a minimum of 1 minute between each shock to ascertain the outcome of the immediately prior shock.

Find a Location

Who is running the clinical trial?

Inova Health Care ServicesLead Sponsor
72 Previous Clinical Trials
21,823 Total Patients Enrolled
3 Trials studying Atrial Fibrillation
256 Patients Enrolled for Atrial Fibrillation
Brett Atwater, MDPrincipal InvestigatorInova Health Care Services
4 Previous Clinical Trials
119 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
60 Patients Enrolled for Atrial Fibrillation

Media Library

Lifepak external defibrillator (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05992623 — N/A
Atrial Fibrillation Research Study Groups: Lifepak defibrillator waveform used after unsuccessful second full output shock., Output synchronized to 200J using Zoll Rectilinear Biphasic Waveform (RBW) defibrillator, Output synchronized to 360J Lifepak Biphasic Truncated Exponential Waveform (BTE) defibrillator, Zoll defibrillator waveform used after unsuccessful second full output shock.
Atrial Fibrillation Clinical Trial 2023: Lifepak external defibrillator Highlights & Side Effects. Trial Name: NCT05992623 — N/A
Lifepak external defibrillator (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05992623 — N/A
~269 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top